- Price
- $13.76
- Day
- +5.48%
- Mkt Cap
- $10.98B
- 52W Range
- $12.25 – $30.98
- Volume
- 4.00M
- Beta
- -1.26
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying auto retailer Carvana Co. (NYSE:CVNA) on the heels of its “good” quarter.
Read full article
Summit Therapeutics PLC (NASDAQ: SMMT - Get Free Report) has earned a consensus rating of "Hold" from the sixteen analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, six have issued a hold recommendation, seven have issued a buy recommendation and one has issued a strong
Read full article
Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. SMMT's pivotal HARMONI study showed statistically significant PFS but only a favorable trend in OS; updated data with a hazard ratio of 0.76 has been submitted. Competition is intensifying, with multiple large pharmas developing similar VEGF/PD-1 bispecifics; no acquisition or major partnership offers have materialized for SMMT.
Read full article
NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Read full article
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
Read full article
Summit Therapeutics Inc. (NASDAQ:SMMT) on Thursday reported an adjusted loss of 19 cents, better than the consensus loss of 28 cents per share.
Read full article
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Read full article
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
Read full article
Summit Therapeutics NASDAQ: SMMT executives used the company's latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail the company's cash position as it prepares for a potential U.S. regulatory decision later this year.
Read full article
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf.
Read full article
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi.
Read full article
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.
Read full article